Clinical Trials Directory

Trials / Completed

CompletedNCT03744221

Health Effects of Sustainable Future Proteins

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Wageningen University and Research · Academic / Other
Sex
All
Age
35 Years – 70 Years
Healthy volunteers
Accepted

Summary

In the current study the investigators aim to assess the nutritional quality and bio-functional activity of two alternative protein sources bovine plasma and corn and from the benchmark protein whey. The study is a double blind, randomised, cross-over, short-term trial in which 36 healthy study subjects will receive three protein interventions of 1 week with a washout period of 1 week between interventions. Study subjects will visit the research facility before and after the intervention period on two separate occasions to measure gut permeability via a multi-sugar test and to collect fasting blood samples and blood pressure outcomes. Faecal and saliva samples before and after each intervention will be collected. A subgroup of 12 study participants will also be subjected to a postprandial digestibility test on the first day of the interventions. The main study parameter is to assess the protein digestion kinetics and protection of the epithelial barrier. Secondary study parameters include other markers of gastrointestinal health, metabolic health, vascular health and satiating properties.

Detailed description

In the current study the investigators aim to assess the nutritional quality and bio-functional activity of two alternative protein sources bovine plasma and corn and from the benchmark protein whey. The objective is to assess the degree of digestibility and protection of the epithelial barrier of two alternative protein concentrates from corn and bovine plasma and of the commonly consumed benchmark protein whey. These outcomes will also be used to evaluate how predictive the in vitro-measurements have been for the obtained in vivo-effects. Secondary objectives are to assess the impact on other markers of gastrointestinal health, metabolic health, vascular health and satiating properties. Study design: The study is a double blind, randomised, cross-over, short-term trial in which 36 study subject will participate. Study subjects will receive three protein interventions of 1 week with a washout period of 1 week between interventions. Study subjects will visit the research facility before and after the intervention period on two separate occasions to measure gut permeability via a multi-sugar/acetylsalicylic acid test and to collect fasting blood samples and blood pressure outcomes. Faecal and saliva samples before and after each intervention will be collected. All measurements will be conducted after an overnight fast and a standardised evening meal prior to the study days. A subgroup of 12 study participants will also be subjected to a postprandial digestibility test on the first day of the interventions. Study population: healthy study subjects, between 35-70y, BMI 18 - 30kg/m2, both males and females. Intervention (if applicable): Three intervention arms of one week; a bovine plasma protein intervention, a corn protein intervention and a whey protein comparator intervention. Study subjects will receive 40 grams of protein per day during the intervention in two 20 g doses. Main study parameters/endpoints: The main study parameter is to assess the protein digestion kinetics and protection of the epithelial barrier. Secondary study parameters include other markers of gastrointestinal health, metabolic health, vascular health and satiating properties.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTCorn protein powder40g/d ( 2 times 20 grams per day for a period of 1 week)
DIETARY_SUPPLEMENTBovine plasma protein powder40g/d ( 2 times 20 grams per day for a period of 1 week)
DIETARY_SUPPLEMENTWhey protein powder40g/d ( 2 times 20 grams per day for a period of 1 week)

Timeline

Start date
2018-11-05
Primary completion
2018-12-20
Completion
2018-12-20
First posted
2018-11-16
Last updated
2019-01-16

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT03744221. Inclusion in this directory is not an endorsement.